Data Presentations
January 17, 2021
ASCO GI
Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with previously treated CCA and an (IDH1) mutation
December 7, 2020
ASH Annual Meeting 2020
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML
December 7, 2020
ASH Annual Meeting 2020
AGILE: Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with AML & IDH Mutation
December 7, 2020
ASH Annual Meeting 2020
Longitudinal molecular profiling in patients with IDH1-mutant newly diagnosed AML treated with ivosidenib
December 6, 2020
ASH Annual Meeting 2020
Molecular characterization of clinical response and relapse in patients with IDH1-mutant newly diagnosed AML treated with ivosidenib & azacitidine
December 6, 2020
ASH Annual Meeting 2020
Phase I Study of the IDH2 inhibitor enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following hematopoietic cell transplantation
July 22, 2020
Cholangiocarcinoma Foundation Annual Conference 2020
Health-related quality of life in patients treated with ivosidenib for mutant-IDH1 cholangiocarcinoma: Results from ClarIDHy
June 22, 2020
AACR Annual Meeting 2020
Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment
June 22, 2020
AACR Annual Meeting 2020
MAT2A inhibitor AG-270 combines with both taxanes and gemcitabine to yield enhanced antitumor activity in patient-derived xenograft models
June 12, 2020
EHA Annual Congress 2020
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib, with the BCL2-inhibitor venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
June 12, 2020
EHA Annual Congress 2020
Ivosidenib improves overall survival relative to standard therapies in relapsed or refractory mutant IDH1 AML
June 12, 2020
EHA Annual Congress 2020
Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS)
June 12, 2020
EHA Annual Congress 2020
Pharmacodynamic evaluation of IVO combined with intensive induction and consolidation chemotherapy in patients with newly diagnosed IDH1/2-mutant AML
June 12, 2020
EHA Annual Congress 2020
Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
May 29, 2020
ASCO Annual Meeting 2020
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients with recurrent/progressive glioma
May 29, 2020
ASCO Annual Meeting 2020
Phase Ib/II Study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
May 29, 2020
ASCO Annual Meeting 2020
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881)
May 29, 2020
ASCO Annual Meeting 2020
IDH1 mutation detection in plasma ctDNA and association with clinical response in patients with advanced ICC from the phase 3 ClarIDHy study
May 29, 2020
ASCO Annual Meeting 2020
Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
December 9, 2019
ASH Annual Meeting 2019
Complex polyclonal resistance mechanisms to ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML revealed by single-cell sequencing analyses
December 9, 2019
ASH Annual Meeting 2019
Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study
December 9, 2019
ASH Annual Meeting 2019
Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory AML
December 8, 2019
ASH Annual Meeting 2019
High rate of IDH1 mutation clearance and MRD negativity in patients with IDH1-mutant newly diagnosed AML treated with ivosidenib (AG-120) & azacitidine
December 8, 2019
ASH Annual Meeting 2019
AGILE: Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib with azacitidine in adults with previously untreated AML with an IDH1 mutation
November 22, 2019
SNO Annual Meeting 2019
A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma
October 27, 2019
AACR-NCI-EORTC 2019
A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
October 27, 2019
AACR-NCI-EORTC 2019
Mitotic defects induced by MAT2A inhibitors guide translational drug combination strategies with AG-270 and taxanes
September 30, 2019
ESMO Congress 2019
ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced CCA with an IDH1 mutation
June 15, 2019
EHA Annual Congress 2019
Ivosidenib (AG-120) induces durable remissions and transfusion independence in patients with IDH1-mutant relapsed/refractory MDS in a phase 1 dose escalation and expansion study
June 3, 2019
ASCO Annual Meeting 2019
Mutant IDH1 inhibitor ivosidenib (AG-120) in combination with azacitidine for newly diagnosed AML
June 3, 2019
ASCO Annual Meeting 2019
Phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: Results from Cohort 1
June 3, 2019
ASCO Annual Meeting 2019
Ivosidenib (AG-120) in IDH1-mutant newly diagnosed acute myeloid leukemia: Updated results from a phase 1 study
April 2, 2019
AACR Annual Meeting 2019
Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma
April 2, 2019
AACR Annual Meeting 2019
Inhibition of mutant IDH enzymes reduces production of 2-HG but does not restore wild-type IDH activity in vitro or in vivo
April 2, 2019
AACR Annual Meeting 2019
IDH1-R132H tumor cells are not robustly sensitive to PARP inhibition in a 2-HG–dependent manner
February 25, 2019
Acute Leukemias XVII
Safety and clinical activity of mutant IDH1 inhibitor ivosidenib (AG-120) in combination with azacitidine for newly diagnosed AML
More from Servier
Research & Development
We invest in the research and development of innovative medicines, all designed with the goal to best address the unmet needs of patients.
Learn MoreClinical Trials
We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.
Learn MoreMedicines
Servier Pharmaceuticals' medicines change the lives of the patients we serve. Currently, within the United States, oncology treatment and care are our immediate focus.
Learn More